Proathlete Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$77.6K Buy
1,244
+314
+34% +$19.8K 0.02% 121
2026
Q2
$53.6K Hold
930
– – 0.01% 117
2026
Q1
$56.4K Hold
930
– – 0.02% 111
2025
Q4
$50.2K Sell
930
-1,506
-62% -$72.4K 0.01% 122
2025
Q3
$110K Hold
2,436
– – 0.03% 91
2025
Q2
$113K Hold
2,436
– – 0.04% 89
2025
Q1
$149K Buy
+2,436
New +$142K 0.05% 69

Other funds holding BMY

Proathlete Wealth Management's BMY Position: Q3 2026 in Review

Proathlete Wealth Management increased its Bristol-Myers Squibb (BMY) stake by 34% in Q3 2026, buying an estimated $19.8K and bringing the position to 1,244 shares worth $77.6K. The position accounts for 0.02% of the portfolio, ranked #121.

Proathlete Wealth Management first reported a position in BMY in Q1 2025 and has held it in 7 quarters since. The position peaked at $149K in Q1 2025. 2,558 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Proathlete Wealth Management held 1,244 shares of Bristol-Myers Squibb worth $77.6K as of Q3 2026.
  • Proathlete Wealth Management bought 314 Bristol-Myers Squibb shares in Q3 2026, an estimated $19.8K.
  • Bristol-Myers Squibb made up 0.02% of Proathlete Wealth Management's portfolio in Q3 2026, its #121 holding.
  • Proathlete Wealth Management first reported a position in Bristol-Myers Squibb in Q1 2025 and has held it in 7 quarters since.
  • Proathlete Wealth Management's Bristol-Myers Squibb position peaked at $149K in Q1 2025.
  • 2,558 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Proathlete Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.